Here's Why Conmed ( CNMD ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Conmed ( CNMD ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Conmed ( CNMD ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Conmed ( CNMD ) Q2 EPS Jumps 17%
Conmed ( NYSE:CNMD ) , a medical technology company specializing in surgical devices, reported its financial results on July 30, 2025. The headline news from the release was that both GAAP revenue and adjusted earnings per share ( non-GAAP ) topped analyst projections, with GAAP revenue reaching ...
CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised
CNMD reports solid second-quarter results, driven by improving sales across both segments.
Conmed ( CNMD ) Q2 Earnings and Revenues Top Estimates
Conmed (CNMD) delivered earnings and revenue surprises of +1.77% and +0.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
Why Is Merit Medical Stock Trading Higher On Tuesday? - Merit Medical Systems ( NASDAQ:MMSI )
Q2 revenue expected to exceed analyst estimates with up to 14% growth. Analyst reaffirms Buy rating, sets $108 price forecast for MMSI. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On Merit Medical Systems Inc.
Merit Medical Names Martha Aronson as New President and Chief Executive Officer - Merit Medical Systems ( NASDAQ:MMSI )
Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 07, 2025 ( GLOBE NEWSWIRE ) -- Merit Medical Systems, Inc.
This Conagra Brands Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday - Anglogold Ashanti ( NYSE:AU ) , Conagra Brands ( NYSE:CAG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
CVS Health Posts Better-Than-Expected Earnings, Joins CommScope, Microsoft, Meta, Chart Industries, And Other Big Stocks Moving Higher On Thursday - Advanced Energy Indus ( NASDAQ:AEIS ) , ATI ( NYSE:ATI )
U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Thursday. Shares of CVS Health Corporation CVS rose sharply during Thursday's session after the company reported better-than-expected first-quarter results and raised FY25 EPS guidance.
CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook
CNMD reports solid first-quarter results, driven by improving sales across both segments.
Conmed ( CNMD ) Surpasses Q1 Earnings and Revenue Estimates
Conmed (CNMD) delivered earnings and revenue surprises of 17.28% and 2.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Global Bariatric Surgeries Market to Hit USD 27.64 Billion by 2030, Fueled by Rising Demand for Minimally Invasive Techniques - The Insight Partners
US & Canada, April 01, 2025 ( GLOBE NEWSWIRE ) -- US & Canada, Mar, 21, 2025 ( GlobeNewswire ) -- According to a comprehensive report from The Insight Partners, "Bariatric Surgeries Market Size and Forecast ( 2020 - 2030 ) , Global and Regional Share, Trend, and Growth Opportunity Analysis ...
Conmed ( CNMD ) Down 12.2% Since Last Earnings Report: Can It Rebound?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Conmed ( CNMD ) Down 12.2% Since Last Earnings Report: Can It Rebound?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for February 19th
ACDVF, BN and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on February 19, 2024.
New Strong Sell Stocks for February 11th
ATS, CNMD and CSX have been added to the Zacks Rank #5 (Strong Sell) List on February 11, 2025.
CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook
CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product.
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - FormFactor ( NASDAQ:FORM ) , Conmed ( NYSE:CNMD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI Group analyst Shweta Khajuria downgraded the rating for Match Group, Inc.
These Analysts Slash Their Forecasts On Conmed After Q4 Results - Conmed ( NYSE:CNMD )
CONMED Corporation CNMD posted better-than-expected earnings for its fourth quarter, but issued FY25 earnings and revenue guidance below estimates. Conmed reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.20 per share.
Conmed ( CNMD ) Surpasses Q4 Earnings and Revenue Estimates
Conmed (CNMD) delivered earnings and revenue surprises of 11.67% and 1.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health ( CAH ) Surpasses Q2 Earnings and Revenue Estimates
Cardinal (CAH) delivered earnings and revenue surprises of 10.29% and 0.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Conmed ( CNMD ) Earnings Expected to Grow: Should You Buy?
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy CONMED ( CNMD ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pro-Dex Stock Skyrockets Over the Past Year: A Must Buy?
Investors can consider investing in PDEX right now as the stock has done extremely well through 2024 and its prospects continue to shine.
CNMD vs. ALGN: Which Stock Is the Better Value Option?
Investors interested in Medical - Dental Supplies stocks are likely familiar with Conmed ( CNMD Quick QuoteCNMD - ) and Align Technology ( ALGN Quick QuoteALGN - ) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Is Cardinal Health ( CAH ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Top 3 Health Care Stocks That May Dip This Month - Conmed ( NYSE:CNMD ) , Butterfly Network ( NYSE:BFLY )
As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
Why Conmed ( CNMD ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Conmed ( CNMD ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.
Conmed ( CNMD ) Surpasses Q3 Earnings Estimates
Conmed (CNMD) delivered earnings and revenue surprises of 6.06% and 0.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Conmed ( CNMD ) Earnings Expected to Grow: Should You Buy?
Conmed (CNMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Conmed ( CNMD ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Conmed ( CNMD ) Beat Estimates Again in Its Next Earnings Report?
Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Retain CONMED Stock in Your Portfolio
CNMD is poised for growth with strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Here's Why Conmed ( CNMD ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Trocars Market is expected to generate a revenue of USD 1.19 Billion by 2031, Globally, at 6.1% CAGR: Verified Market Research®
Lewes, Delaware, Oct. 01, 2024 ( GLOBE NEWSWIRE ) -- The Global Trocars Market Size is projected to grow at a CAGR of 6.1% from 2024 to 2031, according to a new report published by Verified Market Research®.
Veterinary Arthroscopy Device Market is Predicted to Reach US$ 721.9 Billion by 2034 | Fact.MR Report
Rockville, MD, Sept. 30, 2024 ( GLOBE NEWSWIRE ) -- According to a new research report by Fact.MR, the global veterinary arthroscopy device market is expected to reach US$ 401 million in 2024 and is further projected to expand at 6.1% CAGR from 2024 to 2034.
New Strong Sell Stocks for September 26th
AMTB, BZH and CNMD have been added to the Zacks Rank #24 (Strong Sell) List on September 26, 2024.
New Strong Sell Stocks for September 17th
BAMXF, BZH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on September 17 2024.
